News
PBYI
8.14
-3.04%
-0.26
Weekly Report: what happened at PBYI last week (1102-1106)?
Weekly Report · 2d ago
Puma Biotechnology (PBYI) Q3 2026 Earnings Call Transcript
The Motley Fool · 4d ago
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
NASDAQ · 5d ago
Puma Biotechnology Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
Puma Biotechnology reports Q3 adjusted EPS 15c vs 21c last year
TipRanks · 5d ago
Puma Biotechnology Non-GAAP EPS of $0.15, revenue of $55.1M
Seeking Alpha · 5d ago
Puma Biotechnology Sees Q4 Sales $67.000M-$70.000M
Benzinga · 5d ago
Puma Biotechnology Narrows FY2026 Sales Guidance from $224.000M-$231.000M to $224.000M-$227.000M
Benzinga · 5d ago
Press Release: Puma Biotechnology Reports Third -2-
Dow Jones · 5d ago
*Puma Biotechnology 3Q EPS 11c >PBYI
Dow Jones · 5d ago
*Puma Biotechnology 3Q Net $6M >PBYI
Dow Jones · 5d ago
*Puma Biotechnology 3Q Rev $55.1M >PBYI
Dow Jones · 5d ago
Puma Biotech: Q3 Earnings Snapshot
Barchart · 5d ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 6d ago
Puma Biotechnology Consensus Price Target Raised 20.00% to $6.12
NASDAQ · 11/02 16:11
Weekly Report: what happened at PBYI last week (1026-1030)?
Weekly Report · 11/02 09:04
Weekly Report: what happened at PBYI last week (1019-1023)?
Weekly Report · 10/26 09:04
Press Release: Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Dow Jones · 10/22 20:40
Weekly Report: what happened at PBYI last week (1012-1016)?
Weekly Report · 10/19 09:04
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
NASDAQ · 10/16 12:45
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.